21.55
+2.13%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Anxo Pharmaceutical Co
Its shares trade on Taipei Exchange under the ticker 6677.TWO. It has been listed since 27 June 2018. In the fiscal year to 31 December 2025, it reported revenue of TWD 843.3m and a net loss of TWD 34.1m. At that date it held total assets of TWD 2.07bn and shareholders' equity of TWD 991.8m.
Anxo Pharmaceutical Co., Ltd. provides service for industry in developing analytical methodology, validation and various pharmaceutical dosage forms. The company is headquartered in Taipei City, Taipei. The company went IPO on 2018-06-27. The firm is involved in the research and development of niche-type technology platforms and products with high-tech thresholds and high barriers to entry, as well as the provision of contract development and manufacturing organization (CDMO) services for pharmaceutical companies at home and abroad. The Company’s main operating revenues are from the sale of products, technical services, as well as original equipment manufacturer (OEM) services.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 27 Jun 2018
- Website
- anxo.com.tw ↗
Leadership
Pay as last reported
- Mr. Jerry WangChairman of the Board, since 2014
- Mr. Linquan YanChief Executive Officer, General Manager, Director, since 2013
- Yuwen HuangChief Information Security Officer
- Mr. Qiheng JianChief Research & Development Officer
- Wenlong LiHead of Finance & Accounting, Corporate Governance Officer
- Shujun ChenDirector
- Guangyang XuDirector
- Mr. Chun-Cheng ChenIndependent Director
- Zhongcheng ChenIndependent Director
- Zhaozhou KangIndependent Director
- Dezhu SunHead of Human Resources Division, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Anxo Pharmaceutical Co Ltd develops niche technology platforms with high barriers to entry in the pharmaceutical sector.
- The company provides contract development and manufacturing organization (CDMO) services for domestic and international pharmaceutical firms.
- Anxo generates main revenue from product sales, technical services, and OEM services in the Health Care industry.
Weaknesses
- Anxo Pharmaceutical Co Ltd has a limited presence in global markets outside Taiwan.
- The company's reliance on niche technology platforms may restrict market expansion opportunities.
- Anxo's revenue is primarily derived from domestic operations in Taipei City, Taiwan.
Opportunities
- Anxo Pharmaceutical Co Ltd can expand its CDMO services to emerging markets in Asia.
- The growing demand for pharmaceutical R&D services presents a significant opportunity for Anxo.
- Anxo can leverage its niche technology platforms to enter new product segments within the Health Care sector.
Threats
- Anxo faces competition from established pharmaceutical companies in the global market.
- Regulatory changes in Taiwan could impact the company's operations and product approvals.
- The company's dependence on niche technology platforms may lead to vulnerability if market demands shift.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.